A REVIEW OF AGO TUMOR

In summary, during the last 10 years the most extraordinary edge continues to be reached in HER2/neu-overexpressing MBC. Introduction of bevacizumab as a VEGF-directed targeted remedy remains a concern on discussion. Some of the novel therapeutics for the breast most cancers armamentarium resulted in prolongation of survival for individuals with MB